Identity
a synthetic tetrapeptide (4 amino acids, < 40 aa → peptide), AEDG, developed from Russian pineal-gland gerontology research (Vladimir Khavinson and colleagues, from the 1980s). The body produces very small amounts of the related pineal peptide; Epitalon is sold as a "research-use-only" chemical. Epitalon (the synthetic tetrapeptide) and Epithalamin (the pineal extract) are related but distinct — important when reading the literature.
Development & history
- Epitalon comes from the Soviet/Russian pineal-peptide programme led by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, from the 1980s.
- The group first worked with Epithalamin (a pineal-gland extract) and then synthesised the defined tetrapeptide Epitalon (AEDG) as its proposed active principle. It has circulated within Russia as part of Khavinson's "peptide bioregulator" line, but was never developed through Western regulatory pathways — and, as the evidence section notes, the research base is concentrated in this single tradition.
Mechanism (as proposed)
Epitalon is proposed to upregulate hTERT (the telomerase catalytic subunit), raising telomerase activity and supporting telomere maintenance/elongation; Khavinson's work also proposes direct AEDG–DNA interactions and epigenetic/gene-expression effects, plus pineal-linked melatonin/circadian modulation and antioxidant activity. Most of this is in vitro or in animals and concentrated in one research tradition; human relevance is unproven. Note the tension that telomerase activation is also a feature of cancer cells.